BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21845034)

  • 21. Diabetic peripheral neuropathic pain: recognition and management.
    Cole BE
    Pain Med; 2007 Sep; 8 Suppl 2():S27-32. PubMed ID: 17714113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
    Wu EQ; Birnbaum HG; Mareva MN; Le TK; Robinson RL; Rosen A; Gelwicks S
    J Pain; 2006 Jun; 7(6):399-407. PubMed ID: 16750796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine.
    Zilliox L; Russell JW
    Diabetes Metab Syndr Obes; 2010 Jan; 3():7-17. PubMed ID: 21437071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the management of diabetic peripheral neuropathy.
    Tesfaye S
    Curr Opin Support Palliat Care; 2009 Jun; 3(2):136-43. PubMed ID: 19421063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
    Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
    Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
    Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis.
    Jiang L; Xiong Y; Cui J
    Contrast Media Mol Imaging; 2022; 2022():4084420. PubMed ID: 35299589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo.
    Gao Y; Guo X; Han P; Li Q; Yang G; Qu S; Yue L; Wang CN; Skljarevski V; Dueñas H; Raskin J; Gu L
    Int J Clin Pract; 2015 Sep; 69(9):957-66. PubMed ID: 25939897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies.
    Zhao Y; Wu N; Chen S; Boulanger L; Police RL; Fraser K
    Curr Med Res Opin; 2010 Sep; 26(9):2147-56. PubMed ID: 20662557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
    Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
    Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
    Zhao Y; Sun P; Watson P
    Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
    Marchettini P; Wilhelm S; Petto H; Tesfaye S; Tölle T; Bouhassira D; Freynhagen R; Cruccu G; Lledó A; Choy E; Kosek E; Micó JA; Späth M; Skljarevski V; Lenox-Smith A; Perrot S
    Eur J Pain; 2016 Mar; 20(3):472-82. PubMed ID: 26311228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial.
    Joharchi K; Memari M; Azargashb E; Saadat N
    J Diabetes Metab Disord; 2019 Dec; 18(2):575-582. PubMed ID: 31890684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of duloxetine in the treatment of diabetic peripheral neuropathic pain in older patients.
    Wasan AD; Ossanna MJ; Raskin J; Wernicke JF; Robinson MJ; Hall JA; Edwards SE; Lipsius S; Meyers AL; McCarberg BH
    Curr Drug Saf; 2009 Jan; 4(1):22-9. PubMed ID: 19149522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
    Wu N; Chen S; Boulanger L; Fraser K; Bledsoe SL; Zhao Y
    J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain.
    Sun P; Zhao Y; Zhao Z; Bernauer M; Watson P
    Pain Pract; 2012 Nov; 12(8):641-8. PubMed ID: 22335435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.
    Pergolizzi JV; Raffa RB; Taylor R; Rodriguez G; Nalamachu S; Langley P
    Pain Pract; 2013 Mar; 13(3):239-52. PubMed ID: 22716295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
    Raskin J; Pritchett YL; Wang F; D'Souza DN; Waninger AL; Iyengar S; Wernicke JF
    Pain Med; 2005; 6(5):346-56. PubMed ID: 16266355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
    Carter NJ; McCormack PL
    CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain.
    King JB; Schauerhamer MB; Bellows BK
    Ther Clin Risk Manag; 2015; 11():1163-75. PubMed ID: 26309404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.